Lamotrigine and catamenial epilepsy.

Area of Science:

• Neurology
• Endocrinology
• Pharmacology

Background:

• Catamenial epilepsy (CE) presents as seizures occurring rhythmically with the menstrual cycle.
• Hormonal fluctuations, particularly involving progesterone, are implicated in the pathophysiology of CE.
• Limited data exists on the efficacy of anti-epileptic drugs (AEDs) for managing CE.

Purpose of the Study:

• To prospectively evaluate the efficacy of lamotrigine (LTG) in women with catamenial epilepsy.
• To assess changes in serum progesterone levels before and after LTG treatment in CE patients.
• To document the tolerability and side effects associated with LTG therapy for CE.

Main Methods:

• Prospective study involving women diagnosed with catamenial epilepsy.
• Treatment with lamotrigine (LTG) for a duration of 3 months.
• Monitoring seizure frequency and measuring serum progesterone levels pre- and post-treatment.

Main Results:

• Lamotrigine (LTG) demonstrated efficacy in 66% of participants, defined as seizure cessation or a ≥50% reduction in seizure frequency.
• Reported side effects were infrequent and mild, indicating good tolerability of LTG.
• Serum progesterone levels showed a notable increase during the course of LTG treatment.

Conclusions:

• Lamotrigine (LTG) appears to be an effective treatment option for managing catamenial epilepsy (CE).
• The observed increase in progesterone levels may contribute to LTG's anticonvulsant effects in CE.
• LTG is well-tolerated with a favorable side effect profile for CE patients.